5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.87▲ | 1.87▲ | 1.87▲ | 1.87▲ | 1.71▲ |
MA10 | 1.85▲ | 1.85▲ | 1.85▲ | 1.79▲ | 1.73▲ |
MA20 | 1.84▲ | 1.85▲ | 1.86▲ | 1.68▲ | 1.70▲ |
MA50 | 1.87▲ | 1.84▲ | 1.79▲ | 1.68▲ | N/A |
MA100 | 1.82▲ | 1.71▲ | 1.67▲ | 1.74▲ | N/A |
MA200 | 1.70▲ | 1.69▲ | 1.79▲ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.008▲ | 0.002▲ | -0.003▼ | 0.027▲ | 0.025▲ |
RSI | 53.354▲ | 53.197▲ | 53.893▲ | 56.229▲ | 46.499▼ |
STOCH | 76.190 | 63.056 | 67.222 | 67.813 | 39.853 |
WILL %R | -33.333 | -33.333 | -33.333 | -32.787 | -45.255 |
CCI | 87.752 | 46.443 | 43.318 | 82.396 | 90.517 |
Tuesday, June 10, 2025 03:20 PM
OSTX is currently trading at $1.93 or 2.53% lower ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
|
Sunday, June 08, 2025 05:00 PM
NEW YORK, June 06, 2025--OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today ...
|
Friday, June 06, 2025 05:03 AM
(RTTNews) - OS Therapies (OSTX) has submitted a request for Regenerative ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/06/25 | 1.91 | 1.91 | 1.87 | 1.87 | 143,177 |
13/06/25 | 1.79 | 1.87 | 1.73 | 1.82 | 185,700 |
12/06/25 | 1.87 | 1.93 | 1.81 | 1.84 | 123,400 |
11/06/25 | 1.94 | 1.96 | 1.85 | 1.89 | 217,100 |
10/06/25 | 1.855 | 1.97 | 1.83 | 1.92 | 1,334,330 |
09/06/25 | 1.71 | 2.07 | 1.61 | 1.98 | 1,092,272 |
06/06/25 | 1.68 | 1.69 | 1.60 | 1.67 | 138,000 |
05/06/25 | 1.69 | 1.70 | 1.55 | 1.63 | 121,777 |
04/06/25 | 1.58 | 1.70 | 1.5501 | 1.66 | 240,930 |
03/06/25 | 1.60 | 1.6326 | 1.52 | 1.59 | 223,617 |
|
|
||||
|
|
||||
|
|